Myriad Genetics | MYGN

Stock Price
22.35
Daily Change
0.40%
Yearly
17.26%
Q2 Forecast
21.65
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agilent 115.61 -2.12 -1.80% -6.08%
Accelerate Diagnostics 0.70 0.03 3.72% 22.93%
Becton, Dickinson and Co. 242.07 3.68 1.54% -3.71%
Bio-Rad Laboratories 373.16 -6.60 -1.74% -29.30%
Bruker 69.07 -1.23 -1.74% 12.47%
Quest Diagnostics 133.00 -0.88 -0.66% -4.05%
Danaher 229.00 1.82 0.80% -12.26%
Exact Sciences 81.34 0.20 0.24% 67.77%
Standard Biotools 2.35 -0.10 -4.08% 35.06%
Hologic 79.17 0.51 0.65% 6.05%
Illumina 196.59 2.08 1.07% -16.42%
J&J 155.47 1.10 0.71% -12.51%
Mettler Toledo International 1,316.08 1.36 0.10% 4.17%
Myriad Genetics 22.35 0.09 0.40% 17.26%
NanoString Technologies 6.00 -0.08 -1.32% -59.65%
OraSure Technologies 4.93 0.02 0.31% 23.13%
Pacific Biosciences Of California 12.23 -0.12 -0.93% 138.30%
PerkinElmer 115.81 -0.41 -0.35% -20.73%
Quidel 86.14 -0.35 -0.40% -7.12%
Repligen 166.87 -6.47 -3.73% 0.10%
Thermo Fisher Scientific 510.20 -4.02 -0.78% -8.27%
Veracyte 25.68 0 0% 48.10%
Waters 251.09 -4.48 -1.75% -21.97%

Indexes Price Day Year
USND 12959 -58.63 -0.45% 8.04%

Myriad Genetics

Myriad Genetics traded at $22.58 this Wednesday May 31st, increasing $0.32 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Myriad Genetics gained 4.06 percent. Over the last 12 months, its price rose by 18.47 percent. Looking ahead, we forecast Myriad Genetics to be priced at 21.65 by the end of this quarter and at 19.83 in one year, according to Trading Economics global macro models projections and analysts expectations.

Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.